6533b85dfe1ef96bd12bda17
RESEARCH PRODUCT
Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice
Gaetano LetoF. M. TumminelloN. GebbiaB. WoynarowskaR. J. Bernackisubject
Pepstatin AadriamycinLeupeptinsLeupeptinMice Inbred StrainsNeoplasms ExperimentalMetastasiCathepsin DCathepsin BMiceDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsPepstatinsTumor Cells CulturedAnimalsFemaleProtease InhibitorsNeoplasm MetastasisOligopeptidesdescription
The antimetastatic activity of adriamycin in combination with proteinase inhibitors was investigated in mice bearing the metastatic tumors L1210 leukemia, Lewis lung carcinoma or M5076 sarcoma. Leupeptin, a cathepsin B inhibitor, when administered as a single agent was devoid of antimetastatic activity but some therapeutic activity was noted in mice with Lewis lung carcinoma when the agent was administered in combination with adriamysin. Pepstatin A, a cathepsin D inhibitor, had no effect as a single agent in mice with L1210 leukemia but displayed some antimetastatic activity in mice with Lewis lung carcinoma. In mice with M5076 sarcoma the combination of pepstatin A and adriamycin resulted in antimetastatic activity significantly greater than that observed with each agent alone. These results suggest that combinations of proteinase inhibitors with antitumor drugs such as adriamycin, might result in more effective antimetastatic treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1990-01-01 |